MLYS
NASDAQMineralys Therapeutics Inc.
Price$26.73-2.05 (-7.14%)
2026-04-212026-07-24
News · 26 weeks102-14%
2026-02-012026-07-26
Mix4690d
- SEC Filings24(52%)
- Insider12(26%)
- Other7(15%)
- Earnings2(4%)
- Offering1(2%)
Latest news
25 items- INSIDERChief Commercial Officer Warren Eric exercised 7,438 shares at a strike of $13.24 and sold $199,885 worth of shares (7,438 units at $26.87) as part of a pre-agreed trading plan (SEC Form 4)4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- INSIDERChief Medical Officer Rodman David Malcom sold $11,036 worth of shares (416 units at $26.53) as part of a pre-agreed trading plan and exercised 416 shares at a strike of $15.44 (SEC Form 4)4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- INSIDERChief Executive Officer Congleton Jon sold $291,441 worth of shares (10,700 units at $27.24) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 603,621 units (SEC Form 4)4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- INSIDERChief Medical Officer Rodman David Malcom exercised 14,058 shares at a strike of $7.28 and sold $556,671 worth of shares (20,407 units at $27.28) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 51,384 units (SEC Form 4)4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- SECAmendment: SEC Form 144/A filed by Mineralys Therapeutics Inc.144/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- INSIDERChief Medical Officer Rodman David Malcom exercised 2,171 shares at a strike of $16.00 and sold $65,781 worth of shares (2,171 units at $30.30) as part of a pre-agreed trading plan (SEC Form 4)4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- INSIDERChief Executive Officer Congleton Jon sold $1,960,601 worth of shares (75,000 units at $26.14) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 614,321 units (SEC Form 4)4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- INSIDERChief Commercial Officer Warren Eric exercised 104,124 shares at a strike of $13.24 and sold $2,696,322 worth of shares (104,124 units at $25.90) as part of a pre-agreed trading plan (SEC Form 4)4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- INSIDERChief Medical Officer Rodman David Malcom sold $350,087 worth of shares (14,474 units at $24.19) as part of a pre-agreed trading plan and exercised 8,126 shares at a strike of $12.55, decreasing direct ownership by 10% to 57,095 units (SEC Form 4)4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- INSIDERDirector Karydas Daphne exercised 3,000 shares at a strike of $12.02 and sold $75,000 worth of shares (3,000 units at $25.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- PRMineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension – – Coordinated reductions in biomarkers of fibrosis and heart failure suggest lorundrostat may favorably modulate the physiological processes that drive heart failure – RADNOR, Pa., June 14, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldost
- INSIDERChief Medical Officer Rodman David Malcom exercised 8,519 shares at a strike of $4.88 and sold $206,151 worth of shares (8,519 units at $24.20) as part of a pre-agreed trading plan (SEC Form 4)4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
- SECSEC Form 144 filed by Mineralys Therapeutics Inc.144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)
MLYS FAQ
6 questionsWhere does MLYS stock trade?
Mineralys Therapeutics Inc. (MLYS) is listed on NASDAQ.What sector and industry is MLYS in?
Mineralys Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Mineralys Therapeutics Inc. go public?
Mineralys Therapeutics Inc. (MLYS) completed its IPO in 2023.What are analysts saying about MLYS?
Mineralys Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from TD Cowen: Buy on 2026-04-27. Recent price targets range from $1500.00 to $3900.00.What companies are similar to MLYS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare MLYS side-by-side with any of them on Quantisnow.How can I track MLYS on Quantisnow?
Quantisnow aggregates Mineralys Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MLYS to receive live email and push alerts on every new disclosure.